Iolc.Ns

The company maintains a strong liquidity position with a current ratio of 1.89, indicating that it has sufficient short-term assets to cover its short-term liabilities. However, its free cash flow is negative at -639 million INR, which suggests that the company is investing heavily in capital expenditures, as evidenced by the -2.14 billion INR in capital expenditure. Despite this, the company's long-term debt is relatively low at 1.17 billion INR, and its debt-to-equity ratio is 0.07, indicating a conservative capital structure.

In terms of profitability, IOLC.NS has a return on equity (ROE) of 5.99% and a return on assets (ROA) of 4.24%, which are both below the industry median for pharmaceutical companies. This suggests that the company is not generating returns as efficiently as its peers. The operating income of 1.31 billion INR and net income of 1.01 billion INR reflect a healthy bottom line, but the gross profit of 6.65 billion INR indicates that the company is facing margin pressures.

Geographically, IOLC.NS is primarily focused on the Indian market, with a significant portion of its revenue derived from domestic operations. The company's revenue concentration in a single market increases its exposure to local economic and regulatory risks. The company does not disclose specific segment revenues, but its primary business is in vaccines and biological products, which are subject to regulatory changes and pricing pressures.

Looking ahead, the company is expected to maintain a stable revenue trajectory, with no significant growth or decline projected in the next fiscal year. The current fiscal year's revenue of 20.79 billion INR provides a baseline for future performance. The company's capital expenditure plans suggest a continued investment in infrastructure and production capabilities, which could support long-term growth.

The risk assessment for IOLC.NS indicates a medium liquidity risk and a low dilution risk. The company's net cash position is negative after accounting for total debt, which could impact its ability to fund operations without external financing. The low dilution risk is supported by the fact that the number of shares outstanding has not changed between basic and diluted shares, indicating no imminent threat of share dilution.

Recent events and filings do not indicate any material changes in the company's operations or financial position. Analysts have provided a strong buy recommendation, with a mean price target of 110.00 INR, suggesting that the market has a positive outlook on the company's future performance.